Need for a well-balanced sunscreen to protect human skin from both Ultraviolet A and Ultraviolet B damage

Indian Journal of Dermatology, Venereology and Leprology

Volumn 78, Issue SUPPL.1, 2012, Pages 24-30

  Moyal, Dominique ^a  

^a L ORÉAL RECHERCHE   (France)

Author keywords

Clinical studies; sunscreens; Ultraviolet A Ultraviolet B protection

Indexed keywords

PROTEIN P53; SUNSCREEN;

ARTICLE; DELAYED HYPERSENSITIVITY; DNA DAMAGE; DRUG EFFICACY; HUMAN; HYPERPIGMENTATION; IMMUNE DEFICIENCY; LANGERHANS CELL; PHOTODERMATOSIS; PHOTOSENSITIVITY; PHOTOTOXICITY; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION EXPOSURE; SKIN CANCER; SKIN PROTECTION; SUN EXPOSURE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

ASIA; DNA DAMAGE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNE TOLERANCE; PHOTOSENSITIVITY DISORDERS; SKIN; SKIN PIGMENTATION; SUNLIGHT; SUNSCREENING AGENTS; TIME FACTORS; ULTRAVIOLET RAYS;

EID: 84863643222     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.97352     Document Type: Article

References (27)

1. Moyal D, Fourtanier A. Acute and chronic effects of UV on skin. In: Rigel DS, Weiss RA, Lim HW, Dover JS, editors. Photoaging. New York: Marcel Dekker; 2004. p. 15-32.
2. Seité S, Fourtanier A, Moyal D, Young AR. Photodamage to human skin by suberythemal exposure to solar ultraviolet radiation can be attenuated by sunscreens: A review. Br J Dermatol 2010;163:903-14.
3. Damian DL, Barnetson RS, Halliday GM. Low-dose UVA and UVB have different time courses for suppression of contact hypersensitivity to a recall antigen in humans. J Invest Dermatol 1999;112:939-44.
4. Lavker RM, Gerberick GF, Veres D, Irwin CJ, Kaidbey KH. Cumulative effects from repeated exposures to suberythemal doses of UVB and UVA in human skin. J Am Acad Dermatol 1995;32:53-62.
5. Lowe NJ, Meyers DP, Wieder JM, Luftman D, Borget T, Lehman MD, et al. Low doses of repetitive ultraviolet A induce morphologic changes in human skin. J Invest Dermatol 1995;105:739-43.
6. Fourtanier A, Moyal D, Seite S. UVA filters in sun-protection products: Regulatory and biological aspects. Photochem Photobiol Sci 2012;11:81-9.
7. COLIPA, JCIA, CTFA SA: International sun protection factor (SPF) test method. Brussels: COLIPA; 2006.
8. Fourtanier A, Bernerd F, Bouillon C, Duval C, Marrot L, Moyal D, et al. Protection of skin biological targets by different types of sunscreens. Photodermatol Photoimmunol Photomed 2006;22:22-32.
9. Moyal D, Chardon A, Kollias N. UVA protection efficacy of sunscreens can be determinated by the persistent pigment darkening (PPD) method (Part 2). Photodermatol Photoimmunol Photomed 2000;16:250-5.
10. Japan Cosmetic Industry Association (JCIA). Measurements standard for UVA protection efficacy. Tokyo, Japan: JCIA; 1996.
11. Moyal D. UVA protection labeling and in vitro testing methods. Photochem Photobiol Sci 2010;9:516-23.
12. European Commission recommendation. On the efficacy of sunscreen products and the claims made relating thereto. Official J Eur Union 2006;265;39-43.
13. Rai VM, Shenoi SD, Balachandran C, Pai S. Minimal erythema response (MED) to solar simulated irradiation in normal Indian skin. Indian J Dermatol Venereol Leprol 2004;70:277-9.
14. Zhao P, Zhu X, Liu Y, Wang B, Wang C, Burns FJ. Solar ultraviolet radiation and skin damage: An epidemiological study among a Chinese population. Arch Environ Health 1998;53:405-9.
15. Chung JH. Photoaging in Asians. Photodermatol Photoimmunol Photomed 2003;19:109-21.
16. Goh SH. The treatment of visible signs of senescence: The Asian experience. Br J Dermatol 1990;122 Suppl 35:S105-9.
17. Kollias N, Malallah YH, al-Ajmi H, Baqer A, Johnson BE, González S. Erythema and melanogenesis action spectra in heavily pigmented individuals as compared to fair-skinned Caucasians. Photodermatol Photoimmunol Photomed 1996;12:183-8.
18. Christiaens FJ, Chardon A, Fourtanier A, Frederick JE. Standard ultraviolet daylight for nonextreme exposure conditions. Photochem Photobiol 2005;81:874-8.
19. Seité S, Medaisko C, Christiaens F, Bredoux C, Compan D, Zucchi H, et al. Biological effects of simulated ultraviolet daylight: A new approach to investigate daily photoprotection. Photodermatol Photoimmunol Photomed 2006;22:67-77.
20. Moyal D. Prevention of ultraviolet-induced skin pigmentation. Photodermatol Photoimmunol Photomed 2004;20:243-7.
21. Séité S, Moyal D, Verdier MP, Hourseau C, Fourtanier A. Accumulated p53 protein and UVA protection level of sunscreens. Photodermatol Photoimmunol Photomed 2000;16:3-9.
22. LeVee GJ, Oberhelman L, Anderson T, Koren H, Cooper KD. UVA II exposure of human skin results in decreased immunization capacity, increased induction of tolerance and a unique pattern of epidermal antigenpresenting cell alteration. Photochem Photobiol 1997;65:622-9.
23. Moyal DD, Fourtanier AM. Broad-spectrum sunscreens provide better protection from suppression of the elicitation phase of delayed-type hypersensitivity response in humans. J Invest Dermatol 2001;117:1186-92.
24. Seité S, Zucchi H, Moyal D, Tison S, Compan D, Christiaens F, et al. Alteration in human epidermal Langherans cells by ultraviolet radiation: Quantitative and morphological study. Br J Dermatol 2003;148:219-9.
25. Moyal DD, Fourtanier AM. Efficacy of broad-spectrum sunscreens against the suppression of elicitation of delayed-type hypersensitivity responses in humans depends on the level of ultraviolet A protection. Exp Dermatol 2003;12:153-9.
26. Federal Register, Food and Drug administration (USA). Department of Health and Human Services. Labeling and Effectiveness testing: Sunscreen drug products over-the -counter Human Use. 2011. p. 201-310.
27. Fourtanier A, Moyal D, Seité S. Sunscreens containing the broad-spectrum UVA absorber, Mexoryl SX, prevent the cutaneous detrimental effects of UV exposure: A review of clinical study results. Photodermatol Photoimmunol Photomed 2008;24:164-74.